Inhibikase Therapeutics, Inc. completed the acquisition of CorHepta Pharmaceuticals, Inc., effective February 21, 2025. This transaction included a non-cash charge of $7.4 million for acquired in-process research and development (IPRD).
The acquisition is strategically aligned with Inhibikase's focus on Pulmonary Arterial Hypertension (PAH) and its lead candidate, IKT-001Pro. It integrates CorHepta's assets and expertise into Inhibikase's development efforts.
Following the acquisition, CorHepta's former CEO, Chris Cabell, M.D., was appointed President and Head of Research & Development at Inhibikase, and co-founder John Adams, Ph.D., became Chief Scientific Officer, bringing their PAH experience to the company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.